Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis

Wolfgang Janni; Thomas W P Friedl; Tracy C Yab; Francois-Clément Bidard; Massimo Cristofanilli; Daniel F Hayes; Michail Ignatiadis; Meredith M Regan; Catherine Alix-Panabieres; William E Barlow; Carlos Caldas; Lisa A Carey; Luc Dirix; Tanja Fehm; Jose A Garcia-Saenz; Paola Gazzaniga; Daniele Generali; Lorenzo Gerratana; Rafael Gisbert-Criado; William Jacot; Zefei Jiang; Simon A Joosse; Evi Lianidou; Rafael López López; Mark J M Magbanua; Luis Manso; Dimitris Mavroudis; Volkmar Müller; Elisabetta Munzone; Klaus Pantel; Jean-Yves Pierga; Brigitte Rack; Sabine Riethdorf; Hope S Rugo; Kostandinos Sideras; Stefan Sleijfer; Jeffrey Smerage; Justin Stebbing; Leon W M M Terstappen; Jose Vidal-Martínez; Markus Wallwiener; Karthik V Giridhar; Minetta C Liu

doi:10.1158/1078-0432.CCR-24-3108

Retour

Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis

Article de revue

Avec comité de lecture

Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis

Wolfgang Janni, Thomas W P Friedl, Tracy C Yab, Francois-Clément Bidard, Massimo Cristofanilli, Daniel F Hayes, Michail Ignatiadis, Meredith M Regan, Catherine Alix-Panabieres, William E Barlow, …

Clinical cancer research, Vol.31(11), pp.2196-2209

03/06/2025

DOI: https://doi.org/10.1158/1078-0432.CCR-24-3108

PMID: 40100138

Résumé

Adult

Aged

Aged, 80 and over

Biomarkers, Tumor - blood

Breast Neoplasms - blood

Breast Neoplasms - diagnosis

Breast Neoplasms - mortality

Breast Neoplasms - pathology

Breast Neoplasms - therapy

Female

Humans

Middle Aged

Neoplasm Metastasis

Neoplastic Cells, Circulating - metabolism

Neoplastic Cells, Circulating - pathology

Prognosis

The aim of PREDICT was to confirm clinical validity and the potential for clinical utility of serial circulating tumor cell (CTC) enumeration in patients with metastatic breast cancer, focusing on its prognostic value in different breast cancer subtypes and clinical settings. In total, 4,436 individual patient-level data with CTC results from both baseline and one follow-up (CellSearch; Menarini Silicon Biosystems) were analyzed to evaluate the association between CTC detection and overall survival (OS) in the full patient cohort and separately for tumor and treatment types. Using the cutoff ≥1 CTC for CTC positivity, 913 (20.6%) patients had 0 CTCs at both time points (neg/neg) and 325 (7.3%) and 1,189 (26.8%) patients converted from CTC negative to CTC positive (neg/pos) or vice versa (pos/neg), whereas 2,009 (45.3%) patients had at least one CTC at both time points (pos/pos). The median OS for the neg/neg, neg/pos, pos/neg, and pos/pos group was 45.6, 26.1, 32.3, and 17.3 months, respectively (P < 0.0001, global log-rank test). CTC responders (pos/neg) showed a lower risk of death compared with CTC nonresponders (pos/pos; HR, 0.48; 95% confidence interval, 0.44-0.53). Similar results were obtained in subgroup analyses according to hormone receptor and HER2 subtype, treatment type, and with a ≥5 CTC cutoff for CTC positivity. Follow-up CTC assessments strongly predict OS independently from tumor subtype and treatment. New randomized trials to define the clinical utility of CTC monitoring for risk stratification and as an early response marker in metastatic breast cancer are urgently needed.

Indicateurs

1 Consultations de la notice

See more details

Détails

Titre: Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
Créateurs - sans rôle: Wolfgang Janni - Department of Obstetrics and Gynecology, University Hospital Ulm, Ulm, Germany
Thomas W P Friedl - Department of Obstetrics and Gynecology, University Hospital Ulm, Ulm, Germany
Tracy C Yab - Department of Oncology, Mayo Clinic, Rochester, Minnesota
Francois-Clément Bidard - Department of Medical Oncology, Institute Curie, UVSQ University, Paris & St Cloud, France
Massimo Cristofanilli - Division of Hematology and Oncology, Department of Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois
Daniel F Hayes - Breast Oncology Section, University of Michigan Rogel Cancer Center, Ann Arbor, Michigan
Michail Ignatiadis - Université Libre de Bruxelles
Meredith M Regan - Division of Biostatistics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts
Catherine Alix-Panabieres - Laboratory of Rare Human Circulating Cells (LCCRH), University Medical Centre of Montpellier, Montpellier, France
William E Barlow - SWOG Statistical Center, Seattle, Washington
Carlos Caldas - Department of Oncology, Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom
Lisa A Carey - Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina
Luc Dirix - University of Antwerp
Tanja Fehm - Heinrich Heine University Düsseldorf
Jose A Garcia-Saenz - DCIBERONC, IdISCC, Madrid, Spain
Paola Gazzaniga - Liquid Biopsy Unit, Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy
Daniele Generali - Women Cancer Center, Azienda Socio Sanitaria Territoriale di Cremona, University of Trieste, Trieste, Italy
Lorenzo Gerratana - Department of Medicine, University of Udine, Udine, Italy
Rafael Gisbert-Criado - Clinical Laboratory, Hospital Arnau de Vilanova, Valencia, Spain
William Jacot - Department of Medical Oncology, Institut du Cancer de Montpellier (ICM), IRCM, INSERM U1194, Université de Montpellier, Montpellier, France
Zefei Jiang - Department of Breast Cancer, The 307th Hospital of Chinese People's Liberation Army, Beijing, China
Simon A Joosse - University Medical Center Hamburg-Eppendorf
Evi Lianidou - National and Kapodistrian University of Athens
Rafael López López - Translational Medical Oncology Group, Oncomet, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela University Hospital (SERGAS), Santiago de Compostela, Spain
Mark J M Magbanua - Department of Laboratory Medicine, University of California San Francisco, San Francisco, California
Luis Manso - Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain
Dimitris Mavroudis - Department of Medical Oncology, University General Hospital of Heraklion, Iraklio, Greece
Volkmar Müller - Department of Gynecology and Obstetrics, University Hospital Hamburg-Eppendorf, Hamburg, Germany
Elisabetta Munzone - Division of Medical Senology, European Institute of Oncology, IRCCS, Milan, Italy
Klaus Pantel - Department of Tumor Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
Jean-Yves Pierga - Department of Medical Oncology, Institute Curie, Université Paris Cité, Paris & St Cloud, France
Brigitte Rack - Department of Obstetrics and Gynecology, University Hospital Ulm, Ulm, Germany
Sabine Riethdorf - University Medical Center Hamburg-Eppendorf
Hope S Rugo - Department of Laboratory Medicine, University of California San Francisco, San Francisco, California
Kostandinos Sideras - Hematology and Medical Oncology, Mayo Clinic, Jacksonville, Florida
Stefan Sleijfer - Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands
Jeffrey Smerage - Breast Oncology Section, University of Michigan Rogel Cancer Center, Ann Arbor, Michigan
Justin Stebbing - School of Life Sciences, Anglia Ruskin University, Cambridge, United Kingdom
Leon W M M Terstappen - Medical Cell BioPhysics Group, Faculty of Science and Technology, University of Twente, Enschede, the Netherlands
Jose Vidal-Martínez - Clinical Laboratory, Hospital Arnau de Vilanova, Valencia, Spain
Markus Wallwiener - Department of Obstetrics and Gynecology, Medical School, University of Heidelberg, Heidelberg, Germany
Karthik V Giridhar - Department of Oncology, Mayo Clinic, Rochester, Minnesota
Minetta C Liu - Department of Oncology, Mayo Clinic, Rochester, Minnesota
Détails de publication: Clinical cancer research, Vol.31(11), pp.2196-2209
Identifiants: 99141146809311
Unité académique: Institut de Recherche en Cancérologie de Montpellier - IRCM; Maladies Infectieuses et Vecteurs : Ecologie, Génétique, Evolution et Contrôle - MIVEGEC
Langue: English
Type de ressource: Journal article